Protein Design Labs (PDLI): Stock strong

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Protein Design Labs (PDLI): Stock strong

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
407	58	0	PDLI

Emcee: Stanley Cowen	Type: Unmoderated

Introduction Market Data Compact

I have been following this company for several years. Its stock price has done extremely well on good news on their humanized monoclonal antibody technology. Recently reported Phase III trial on Zenapax, which is used in kidney transplants. Results were favorable and filings for application will proceed this year. Although no earnings, their revenues are growing and have $100 million cash. Although they have had their share of disappointments, the basic technology appears to be sound. Another positive report had to do with using a beta isotope hooked up with a PDLI humanized antibody for cancer treatment.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
407	I also decided to pass. Thanks Neil	Neil H	-	11/24/2009
406	I think I'll hold off at least until after the dividend distribution and see	tom pope	-	11/24/2009
405	No, I haven't been following it at all, but thank you for bringing it up, it	tom pope	-	11/24/2009
404	Tom - Are you still in or following this stock. Big extra dividend coming up end	Neil H	-	11/24/2009
403	Merrill Reducing Actemra royalties on delay Pursuant to the news that a potenti	tom pope	-	12/5/2008
402	Merrill BMS deal for HuLuc63 provides cash, flexibility, validation PDL and BMS	tom pope	-	8/20/2008
401	<b>Bristol-Myers buys rights to PDL BioPharma drug</b> Tuesday Augu	idos	-	8/20/2008
400	Merrill Raising antibody royalties estimates on strong sales in 2Q Based on str	tom pope	-	7/31/2008
399	More from Merrill, on the bap news Good for PDL, gauging potential impact of ba	tom pope	-	6/18/2008
398	Merrill - different view Attractive risk reward with planned PDL spinout PDL’s	tom pope	-	6/16/2008
397	PDL BioPharma May Be at Fair Value Credit Suisse notes that potential upside is	Doc Bones	-	6/16/2008
396	This is from Merrill yesterday, looks like they were right to recommend the trad	tom pope	-	3/6/2008
395	Merrill, 3/05 No Sale; planning distributions to shareholders, R&D focus PD	tom pope	-	3/5/2008
394	PDLI is selling Cardene, Retavase, and ularitide to EKR for $85M cash plus miles	idos	-	2/5/2008
393	PDL Biopharma sells oncology drug rights for $200 mln Dec 17 (Reuters) - PDL Bi	tnsaf	-	12/17/2007
392	Merrill. I'm no longer in PDLI, but this price level makes it look interesti	tom pope	-	11/14/2007
391	Third Point Slashes PDL BioPharma Stake Thursday October 18, 11:11 am ET Activis	tnsaf	-	10/18/2007
390	Merrill: Daclizumab shows encouraging phase ll data in MS PDL announced in Marc	tom pope	-	10/12/2007
389	>>Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Le	tuck	-	10/11/2007
388	[HuLuc63 triggered autologous ADCC against primary MM cells resistant to convent	tuck	-	10/3/2007
387	>>PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets	tuck	-	10/1/2007
386	New Plea for PDL BioPharma to Sell By DANA CIMILLUCA September 26, 2007; Page C3	mopgcw	-	9/26/2007
385	Merrill putting the best face on things. I took a position because it seems to m	tom pope	-	8/31/2007
384	Drama continues, actually: >>Third Point Demands that L. Patrick Gage Res	tuck	-	8/29/2007
383	>>Tuck- Were there any hints previously as to the Nuvion issues and ultima	tuck	-	8/29/2007

Go to reply# or date (mm/dd/yy):